Paper42279367
Risk of Malignancy with Immunosuppressive Drugs Used in Organ Transplants Compared to Those Used for Non-Transplant Indications.
Haines C and 6 others. Cancers (Basel), 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Risk of Malignancy with Immunosuppressive Drugs Used in Organ Transplants Compared to Those Used for Non-Transplant Indications. Papers, record 42279367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42279367
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Risk of Malignancy with Immunosuppressive Drugs Used in Organ Transplants Compared to Those Used for Non-Transplant Indications.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22955152 | Biologic therapy. | J Infus Nurs | 2012 | https://conductscience.org/library/papers/22955152 | PubMed |
| 2 | 37650722 | Comparison of 2 Immunosuppression Minimization Strategies in Kidney Transplantation: The ALLEGRO Trial. | Transplantation | 2024 | https://conductscience.org/library/papers/37650722 | PubMed |
| 3 | 18498314 | Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression. | Transpl Int | 2008 | https://conductscience.org/library/papers/18498314 | PubMed |
| 4 | 10699159 | Improved graft survival after renal transplantation in the United States, 1988 to 1996. | N Engl J Med | 2000 | https://conductscience.org/library/papers/10699159 | PubMed |
| 5 | 33715321 | Cervical dysplasia after renal transplantation: A retrospective cohort study. | Turk J Obstet Gynecol | 2021 | https://conductscience.org/library/papers/33715321 | PubMed |
| 6 | 10580071 | Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10580071 | PubMed |
| 7 | 21466650 | Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. | Am J Transplant | 2011 | https://conductscience.org/library/papers/21466650 | PubMed |
| 8 | 38725273 | Therapeutic drug monitoring in kidney and liver transplantation: current advances and future directions. | Expert Rev Clin Pharmacol | 2024 | https://conductscience.org/library/papers/38725273 | PubMed |
| 9 | 40211394 | Natural killer cells: the immune frontline against circulating tumor cells. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40211394 | PubMed |
| 10 | 25126214 | The value of biologics. | Am Health Drug Benefits | 2008 | https://conductscience.org/library/papers/25126214 | PubMed |
| 11 | 14444006 | The effects of 6-mercaptopurine on homograft reactions. | J Clin Invest | 1960 | https://conductscience.org/library/papers/14444006 | PubMed |
| 12 | 21832958 | Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial. | Transplantation | 2011 | https://conductscience.org/library/papers/21832958 | PubMed |
| 13 | 40647460 | Immunosuppressant Drug Specific Risk of Malignancy After Organ Transplantation: A Population-Based Analysis of Texas Medicare Beneficiaries. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40647460 | PubMed |
| 14 | 31609477 | Mycophenolic acid is a drug with the potential to be repurposed for suppressing tumor growth and metastasis in osteosarcoma treatment. | Int J Cancer | 2020 | https://conductscience.org/library/papers/31609477 | PubMed |
| 15 | 14508356 | Primary brain lymphomas after kidney transplantation: presentation and outcome. | Transplantation | 2003 | https://conductscience.org/library/papers/14508356 | PubMed |
| 16 | 32522746 | Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. | Clin Microbiol Rev | 2020 | https://conductscience.org/library/papers/32522746 | PubMed |
| 17 | 34769123 | Biological Therapies in the Treatment of Cancer-Update and New Directions. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34769123 | PubMed |
| 18 | 10739783 | Differences in quality of life across renal replacement therapies: a meta-analytic comparison. | Am J Kidney Dis | 2000 | https://conductscience.org/library/papers/10739783 | PubMed |
| 19 | 25062652 | Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. | Clin Ther | 2014 | https://conductscience.org/library/papers/25062652 | PubMed |
| 20 | 41227204 | Tacrolimus-Sirolimus Combined Exposure and Acute Rejection in Kidney Transplant Recipients Undergoing Early Conversion to Sirolimus: A Multicenter Retrospective Cohort Threshold Analysis. | J Clin Med | 2025 | https://conductscience.org/library/papers/41227204 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42279367
GET https://conductscience.org/api/papers/v1/42279367/references?page=2